These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 29653557)

  • 61. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.
    Padrnos L; Scherber R; Geyer H; Langlais BT; Dueck AC; Kosiorek HE; Senyak Z; Clark M; Boxer M; Cotter M; Harrison C; Stonnington C; Geda Y; Mesa R
    Cancer Med; 2020 Nov; 9(22):8301-8309. PubMed ID: 32976697
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada.
    Bankar A; Zhao H; Iqbal J; Coxford R; Cheung MC; Mozessohn L; Earle CC; Gupta V
    Leuk Lymphoma; 2020 Aug; 61(8):1908-1919. PubMed ID: 32323602
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.
    Grunwald MR; Burke JM; Kuter DJ; Gerds AT; Stein B; Walshauser MA; Parasuraman S; Colucci P; Paranagama D; Savona MR; Mesa R
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):579-584.e1. PubMed ID: 31303457
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Understanding limitations in at-work productivity in patients with active ankylosing spondylitis: the role of work-related contextual factors.
    Boonen A; Boone C; Albert A; Mielants H
    J Rheumatol; 2015 Jan; 42(1):93-100. PubMed ID: 25362661
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Analysis of the factors influencing the severity of coronavirus disease 2019 in patients with myeloproliferative neoplasms based on an online questionnaire].
    Qi FY; Bao M; Gao HL; Jiang Q
    Zhonghua Nei Ke Za Zhi; 2024 Apr; 63(4):371-377. PubMed ID: 38561282
    [No Abstract]   [Full Text] [Related]  

  • 67. Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review.
    Al-Mashdali AF; Aldapt MB; Rahhal A; Hailan YM; Elhakeem I; Ali EA; Rozi W; Yassin MA
    Diagnostics (Basel); 2023 Jan; 13(3):. PubMed ID: 36766480
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
    Lim Y; Lee JO; Bang SM
    J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
    Roaldsnes C; Holst R; Frederiksen H; Ghanima W
    Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
    Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
    Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
    [TBL] [Abstract][Full Text] [Related]  

  • 71. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
    Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
    Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.
    Leal AD; Thompson CA; Wang AH; Vierkant RA; Habermann TM; Ross JA; Mesa RA; Virnig BA; Cerhan JR
    Int J Cancer; 2014 Apr; 134(7):1741-50. PubMed ID: 24114627
    [TBL] [Abstract][Full Text] [Related]  

  • 73. How myeloproliferative neoplasms patients' experience and expectations differ from physicians': the international MPN Landmark survey.
    Byun JM; Bang SM; Choi EJ; Eom KS; Jung CW; Kim HS; Park J; Choi CW
    Korean J Intern Med; 2022 Mar; 37(2):444-454. PubMed ID: 35272443
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Amongst patients taking biologic therapies for axial spondyloarthritis, which factors are associated with work non-participation?
    Nadin T; Wallis D; Holroyd CR; D'Angelo S; Walker-Bone K; Edwards CJ
    BMC Musculoskelet Disord; 2020 Apr; 21(1):209. PubMed ID: 32252744
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.
    Marcellino BK; Hoffman R; Tripodi J; Lu M; Kosiorek H; Mascarenhas J; Rampal RK; Dueck A; Najfeld V
    Blood Adv; 2018 Dec; 2(24):3581-3589. PubMed ID: 30563882
    [TBL] [Abstract][Full Text] [Related]  

  • 77. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.
    Reilly MC; Gerlier L; Brabant Y; Brown M
    Clin Ther; 2008 Feb; 30(2):393-404. PubMed ID: 18343277
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bomedemstat as an investigative treatment for myeloproliferative neoplasms.
    Rienhoff HY; Gill H
    Expert Opin Investig Drugs; 2023; 32(10):879-886. PubMed ID: 37804041
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan.
    Mehta J; Wang H; Fryzek JP; Iqbal SU; Mesa R
    Leuk Lymphoma; 2014 Oct; 55(10):2368-74. PubMed ID: 24450579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.